Kong – Talk Bio

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

2 weeks ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase

3 months ago talkbio0Tagged Bay Area, Biotechnology, Chinese biotechs, Greater, HKEX, IPOs, Kong, listing reforms, Listings

Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.

Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio

8 months ago talkbio0Tagged BeiGene, BioNTech, biotherapeutics, Duality, IPO, Kong, Malignant Neoplasms, therapeutic autologous dendritic cells

Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment